None
NL
Royalty Pharma (NASDAQ:RPRX) Earns Buy Rating from Analysts at The Goldman Sachs Group
['Defense World Staff']
Defense World
The Goldman Sachs Group initiated coverage on shares of Royalty Pharma (NASDAQ:RPRX – Free Report) in a research note released on Tuesday, MarketBeat Ratings reports.
Wall Street Zen downgraded shares of Royalty Pharma from a “buy” rating to a “hold” rating in a research note on Saturday, September 13th.
Royalty Pharma (NASDAQ:RPRX – Get Free Report) last released its quarterly earnings results on Wednesday, August 6th.
Royalty Pharma Dividend AnnouncementThe firm also recently announced a quarterly dividend, which was paid on Wednesday, September 10th.
Recommended StoriesReceive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.